Codony, SandraCalvó-Tusell, CarlaValverde, ElenaOsuna, SílviaMorisseau, ChristopheLoza García, María IsabelBrea Floriani, José ManuelPérez, ConcepciónRodríguez-Franco, María IsabelPizarro-Delgado, JavierCorpas, RubénGriñán-Ferré, ChristianPallàs, MercèSanfeliu, CoralVázquez-Carrera, ManuelHammock, Bruce D.Feixas, FerranVázquez, Santiago2026-01-232026-01-232021-05-04J. Med. Chem. 2021, 64, 9, 5429–54460022-2623https://hdl.handle.net/10347/45429The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs.eng© 2021 American Chemical Society. This publication is licensed under CC-BY 4.0Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/InhibitionInhibitorsPeptides and proteinsScaffoldsUrea3209 Farmacologíajournal article10.1021/acs.jmedchem.0c016011520-4804open access